Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Asston Pharmaceuticals

544445
Micro Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Asston Pharmaceuticals Share price and Fundamental Analysis

View All Details
View All Details
Asston Pharmaceuticals Limited was incorporated on 16th April 2019 as 'Asston Pharmaceutical Pvt. Limited' to contract produce pharmaceutical products for export market. Later on 1st April 2024, Company acquired Ferron Lifecare Private Limited, specializing into nutraceuticals business and produced nutraceutical products at their Ambarnath facility. Ferron Lifecare Private Limited, incorporated on 30th January 2020 was promoted by Dr. Ashish Sakalkar and Mr. Sachin Badakh. Finally, 'Asston Pharmaceuticals Private Limited' was converted from a Private Limited into a Public Limited Company in the name of 'Asston Pharmaceuticals Limited' on 29th August 2024 and received FDA approval for its Ambarnath facility on 2nd December 2024 to produce pharmaceutical products.
Company Incorporation2019
ChairmanNA
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
103.21
PE Ratio
23.87
Industry P/E
31.3
PEG Ratio
0
ROE
40.36%
ROCE
36.99%
ROA
0%
Total Debt (Cr)
0
Debt to Equity
0.68
Dividend Yield
0%
EPS
5.08
Book Value & P/B
44.98 x 2.7
Face Value
10
Outstanding Shares(Cr)
0.85
Current Ratio
2.71
EV to Sales
0

Included In

+More

Stock Returns

1 Week-6.82%
1 Month-7.56%
6 Months-7.56%
1 Year-7.56%
3 Years-7.56%
5 Years-7.56%
no_data

No Stocks

Smart Score

2
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

Credit Rating
Director Report
Chairman Report
Auditor Report
Jul 25

Promoters : 50.66%

FIIs : 9.70%

DIIs : 0.00%

Public : 39.64%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in July 2025 Qtr
FII Shareholding Increased by 9.7% to 9.7% in July 2025 Qtr
Promoter Shareholding Decreased by 18.41% to 50.66% in July 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Asston Pharmaceuticals Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Asston Pharmaceuticals Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Asston Pharmaceuticals Limited was incorporated on 16th April 2019 as 'Asston Pharmaceutical Pvt. Limited' to contract produce pharmaceutical products for export market. Later on 1st April 2024, Company acquired Ferron Lifecare Private Limited, specializing into nutraceuticals business and produced nutraceutical products at their Ambarnath facility. Ferron Lifecare Private Limited, incorporated on 30th January 2020 was promoted by Dr. Ashish Sakalkar and Mr. Sachin Badakh. Finally, 'Asston Pharmaceuticals Private Limited' was converted from a Private Limited into a Public Limited Company in the name of 'Asston Pharmaceuticals Limited' on 29th August 2024 and received FDA approval for its Ambarnath facility on 2nd December 2024 to produce pharmaceutical products.

Company is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African markets. It operates under brand 'Asston'. Presently, Company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion) and Oral Powder (Sachet, Dry Syrup) etc.

Company's operations are supported by experienced founders with expertise in managing supply chains and maintaining product quality. Currently, Company has its production plant at Ambernath, Maharashtra, for producing generic medicines in the tablet form and nutraceutical medicines in the tablet form, syrup and sachet form. Facility has total production capacity of up to around 8-9 crore tablets per month. Further, it produces an average of 5-6 crore tablets per month, with production capacity varying based on the weight of medicines. Higherweight medicines result in lower production quantities and vice versa. The syrup production capacity for nutraceuticals is approximately 37.5 kiloliters per month, while sachet production capacity ranges from 30 to 40 lakh sachets per month, depending on the powder weight per sachet. The facility is certified by relevant authorities and undergoes periodic audits by state and central FDA authorities. Company engages contract manufacturers to produce generic medicines and antibiotics in various forms, including tablets, sachets, syrups, and capsules.

Company is planning an Initial Public Issue of 22,41,600 Equity Shares of face value of Rs. 10/- through Fresh Issue.

Asston Pharmaceuticals Share Price

Asston Pharmaceuticals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Asston Pharmaceuticals Market Cap

Market capitalization of Asston Pharmaceuticals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Asston Pharmaceuticals is valued compared to its competitors.

Asston Pharmaceuticals PE Ratio

Asston Pharmaceuticals PE ratio helps investors understand what is the market value of each stock compared to Asston Pharmaceuticals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Asston Pharmaceuticals PEG Ratio

The PEG ratio of Asston Pharmaceuticals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Asston Pharmaceuticals ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Asston Pharmaceuticals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Asston Pharmaceuticals ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Asston Pharmaceuticals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Asston Pharmaceuticals Total Debt

Total debt of Asston Pharmaceuticals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Asston Pharmaceuticals Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Asston Pharmaceuticals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Asston Pharmaceuticals CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Asston Pharmaceuticals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Asston Pharmaceuticals Technical Analysis

Technical analysis of Asston Pharmaceuticals helps investors get an insight into when they can enter or exit the stock. Key components of Asston Pharmaceuticals Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Asston Pharmaceuticals shares often struggle to rise above due to selling pressure.

Asston Pharmaceuticals Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Asston Pharmaceuticals ’s financial health and profitability.

Asston Pharmaceuticals Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Asston Pharmaceuticals Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Asston Pharmaceuticals Financials

The financials of Asston Pharmaceuticals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Asston Pharmaceuticals Profit and Loss Statements

The profit and loss statement of Asston Pharmaceuticals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Asston Pharmaceuticals .

Asston Pharmaceuticals Balance Sheet

The balance sheet presents a snapshot of Asston Pharmaceuticals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Asston Pharmaceuticals Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.